OQROGet OQRO Pro
Insider trade

Idexx Laboratories (IDXX)Director sold ~$1.42M

M Anne Szostak, Director at Idexx Laboratories, sold ~$1.42M of Idexx Laboratories shares.

~$1.42M
Approx. value · 2,187 sh @ $647.33
262
Holds after · shares reported
Traded
Aug 22, 2025
Filed
Aug 26, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 9, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  2. Aug 1, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  3. Aug 6, 2025Insider · 3 peopleInsiders: 16 sales (~$28.3M)
  4. Aug 7, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  5. Aug 8, 2025InsiderOfficer sold ~$3.55M of IDXX shares in the open market
  6. Aug 11, 2025InsiderOfficer sold ~$788K of IDXX shares in the open market
  7. Aug 12, 2025Insider · 1 personInsiders: 2 sales (~$264K)
  8. Aug 22, 2025 · this disclosureInsiderDirector sold ~$1.42M of IDXX shares in the open market

What came next

  1. Sep 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  2. Oct 6, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective October 6, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee.”
  3. Oct 16, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  4. Oct 29, 2025CongressDisclosed partial sale of IDXX — reported range $1,001 - $15,000
  5. Nov 3, 2025Company filing · Form 8-K · ResultsReported its results
  6. Nov 7, 2025Insider · 1 personInsiders: 4 sales (~$6.6M)
  7. Nov 12, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Idexx Laboratories

For Idexx Laboratories, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 30 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IDXX page.

Other recent filings by M Anne Szostak, Director

The full history of M Anne Szostak, Director is on the profile page.

How this filing works

Other disclosures at Idexx Laboratories

Everything OQRO holds on this company is on its IDXX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data